ArticleCancer science2026
SMURF1 Regulates CTCF-HOXA10 Axis and Promotes Tumor Progression in Nasopharyngeal Carcinoma.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The aberrant upregulation of Homeobox A10 (HOXA10) has been implicated in the progression of nasopharyngeal carcinoma (NPC), but the mechanisms driving its upregulation are not fully elucidated. This study demonstrated that the E3 ubiquitin ligase SMAD ubiquitination regulatory factor 1 (SMURF1) promoted the ubiquitin-mediated degradation of CCCTC-binding factor (CTCF), thereby alleviating CTCF-mediated transcriptional repression on HOXA10. Consequently, elevated HOXA10 expression contributed to tumor progression in NPC. We confirmed that HOXA10 was significantly upregulated in NPC and promoted malignant phenotypes of NPC cells. CTCF was identified as a direct transcriptional repressor of HOXA10 and was downregulated in NPC. Moreover, SMURF1 was found to be increased in NPC, where it directly bound to CTCF and regulated its protein stability. Specifically, SMURF1 promoted K48-linked ubiquitination degradation of CTCF. In vitro functional assays revealed that SMURF1 knockdown inhibited NPC cell proliferation, migration, invasion, and epithelial-mesenchymal transition. In vivo experiments further confirmed that SMURF1 knockdown suppressed NPC tumor growth and lung metastasis, accompanied by increased CTCF expression and decreased HOXA10 level in both tumor and lung tissues. Collectively, these findings revealed the SMURF1/CTCF/HOXA10 axis as a crucial mechanism in NPC pathogenesis, positioning SMURF1 as a promising therapeutic target for intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.